Xontogeny Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Xontogeny's estimated annual revenue is currently $2.6M per year.(i)
  • Xontogeny's estimated revenue per employee is $155,000

Employee Data

  • Xontogeny has 17 Employees.(i)
  • Xontogeny grew their employee count by 0% last year.

Xontogeny's People

NameTitleEmail/Phone
1
VP, LegalReveal Email/Phone
2
Director AdministrationReveal Email/Phone
3
Senior Director, Strategic and Financial PlanningReveal Email/Phone
4
Senior Manager, Program DevelopmentReveal Email/Phone
5
PartnerReveal Email/Phone
6
Advisor/Consultant, Clinical OperationsReveal Email/Phone
7
PrincipalReveal Email/Phone
8
Partner, R&DReveal Email/Phone
9
Senior AssociateReveal Email/Phone
10
AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3470M2330-17%$862K$49.2B
Add Company

What Is Xontogeny?

Xontogeny (zon-TOJ-uh-nee) is a biotech aggregator with a differentiated business model to support the accelerated development of life science technologies in the pursuit of helping patients with serious diseases. Specifically, we partner with entrepreneurs, providing the leadership and operating experience needed to increase the probability of success with early drug and technology development. At Xontogeny, we believe that scientific founders supply the passion and determination integral to the success of their companies. While the foundation of success is good science, how that science is developed from inception to maturity serves as the critical pathway. Therefore, we focus on supporting the entrepreneur's pursuit and optimizing the development pathway with an exceptionally talented and experienced operational team. With our team's track record of success, entrepreneurs of affiliated companies will gain the support and guidance they need while remaining lean, virtual, and without the financial burden of supporting a full-time team. This dynamic model has the additional benefit of supporting the goals of the founding scientists and entrepreneurs to retain more control and equity, while increasing the chance of accessing investment, and ultimately development success.

keywords:N/A

N/A

Total Funding

17

Number of Employees

$2.6M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Xontogeny News

2022-04-13 - Surf's up: Startup stoked as Chris Garabedian fund funnels cash into ...

PXV Fund enables Perceptive to make early-stage investments in life science startups, including those seeded and incubated at Garabedian's Xontogeny...

2022-04-06 - PolyCore Therapeutics Secures Seed Financing to Address Motor ...

“We are thrilled to welcome a collaboration with the team at Xontogeny as we work to advance our lead compound through IND-enabling studies.

2022-03-22 - VivoSense Announces Closing of $25M Series A Financing

Funding round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund. NEWPORT BEACH, Calif.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.3M17-53%N/A
#2
$1.5M17-6%N/A
#3
$1.5M17-11%N/A
#4
$1.5M17N/AN/A
#5
$1.5M17N/AN/A